layer1-background

News

 
News
  Date Title View
May 2, 2014
PALO ALTO, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D., has joined the Company as its Chief Business Officer. "We are excited that Gaurav is joining Ocera to help shape our future partnering and other strategic initiatives," said Linda Grais, M.D., chief executive officer o...
Apr 29, 2014
PALO ALTO, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference cal...
Mar 13, 2014
PALO ALTO, Calif., March 13, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a biopharmaceutical company focused on innovative therapeutics for orphan liver disease, announced today its financial results and other information for the fourth quarter and year ended December 31, 2013. Revenues from continuing operations for the fourth...
Mar 4, 2014
PALO ALTO, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter financial results on March 13, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference ...
Feb 26, 2014
PALO ALTO, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced today that company management plans to present at the Cowen Health Care Conference. Ocera's presentation is scheduled for Wednesday, March 5, 2014 at 8:00 AM ...
Jan 8, 2014
PALO ALTO, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced enrollment of the first patient in its multi-center Phase 2b study, the "STOP-HE" or OCR002-HE209 trial. This study is evaluating the efficacy, safety and pharmacokinetics of OCR-002, or ornithine phenylacetate, in hospitalized patients with liver c...
Dec 24, 2013
PALO ALTO, Calif., Dec. 24, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Wendell Wierenga, Ph.D., has joined its board of directors. "We are excited that Wendell has accepted our offer to join our board, and we will benefit greatly from his leadership as we advance our Phase 2b clinical trials," said Linda Grai...
Dec 17, 2013
PALO ALTO, Calif., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH™) discovery plat...
Dec 11, 2013
PALO ALTO, Calif., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that David S. Moore, its chief business officer, will be leaving Ocera to pursue other opportunities. Mr. Moore was a former member of the management team at Tranzyme and continued his employment with Ocera following the merger of Ocera and Tranzym...
Nov 26, 2013
PALO ALTO, Calif., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., president and chief executive officer, plans to present at the 25th Annual Piper Jaffrey Healthcare Conference taking place at t...
FirstPrevious
...
8
NextLast
= add release to Briefcase